OCT 17, 2016
Latest on Dry AMD
AAO 2016
07:41
Comprehensive Ophthalmology, Retina/Vitreous
In this interview from AAO 2016, Dr. Philip Rosenfeld discusses the results from a phase 2 trial of anti-amyloid beta monoclonal antibody for the treatment of geographic atrophy (GA) secondary to AMD. Beta amyloids are known to accumulate in the plasma of patients with GA and colocalizes with drusen. The drug, which was delivered intravenously, failed to slow the growth of GA or improve visual acuity. Regardless, Dr. Rosenfeld and colleagues gleaned useful insights into the disease process from their well-designed trial.